Alliqua BioMedical, Inc. Form 3 September 08, 2014

# FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

Expires:

January 31, 2005

Estimated average burden hours per

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF

**SECURITIES** 

response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting 2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Person \* Statement Alliqua BioMedical, Inc. [ALOA]  **BARTON BRADFORD** (Month/Day/Year) 08/29/2014 (Last) (First) (Middle) 4. Relationship of Reporting 5. If Amendment, Date Original Person(s) to Issuer Filed(Month/Day/Year) C/O ALLIQUA BIOMEDICAL, (Check all applicable) INC., 2150 CABOT **BOULEVARD WEST** 10% Owner Director (Street) \_X\_\_ Officer Other 6. Individual or Joint/Group (give title below) (specify below) Filing(Check Applicable Line) Chief Operating Officer \_X\_ Form filed by One Reporting Person LANGHORNE, PAÂ 19047 Form filed by More than One Reporting Person (City) (State) (Zip) **Table I - Non-Derivative Securities Beneficially Owned** 1. Title of Security 2. Amount of Securities 3. 4. Nature of Indirect Beneficial Beneficially Owned Ownership (Instr. 4) Ownership (Instr. 4) Form: (Instr. 5) Direct (D) or Indirect (I) (Instr. 5) Â Common Stock 15,210 (1) D Reminder: Report on a separate line for each class of securities beneficially SEC 1473 (7-02) owned directly or indirectly. Persons who respond to the collection of information contained in this form are not

 Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

required to respond unless the form displays a

currently valid OMB control number.

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security	4. Conversion or Exercise	5. Ownership Form of	6. Nature of Indirect Beneficial Ownership
		(Instr. 4)	Price of Derivative	Derivative Security:	(Instr. 5)

Edgar Filing: Alliqua BioMedical, Inc. - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Stock Option (right to buy)	(2)	05/10/2023	Common Stock	54,855 (1)	\$ 4.38 (1)	D	Â
Stock Option (right to buy)	(2)	05/10/2023	Common Stock	54,855 <u>(1)</u>	\$ 5.47 (1)	D	Â
Stock Option (right to buy)	(2)	05/10/2023	Common Stock	54,855 <u>(1)</u>	\$ 6.56 (1)	D	Â
Stock Option (right to buy)	(2)	05/10/2023	Common Stock	54,855 (1)	\$ 8.75 <u>(1)</u>	D	Â
Stock Option (right to buy)	(2)	05/10/2023	Common Stock	54,855 (1)	\$ 10.94 (1)	D	Â
Stock Option (right to buy)	(3)	03/06/2024	Common Stock	70,000	\$ 9	D	Â
Warrant (right to buy)	06/28/2013	06/28/2018	Common Stock	9,877 (1)	\$ 4.24 <u>(1)</u>	D	Â

### **Reporting Owners**

Reporting Owner Name / Address	Relationships				
<b>Fg</b>	Director	10% Owner	Officer	Other	
BARTON BRADFORD C/O ALLIQUA BIOMEDICAL, INC. 2150 CABOT BOULEVARD WEST LANGHORNE, Â PA Â 19047	Â	Â	Chief Operating Officer	Â	

#### **Signatures**

/s/Bradford Barton	09/08/2014	
**Signature of Reporting Person	Date	

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The number of shares and prices reported in this Form 4 reflect a 1-for-43.75 reverse stock split of the common stock of the Issuer that occurred on November 18, 2013.
- Represents a single option granted on May 10, 2013 in five separate tranches. Each tranche vests in three equal annual installments, with one-third (1/3rd) vesting on May 10, 2013, May 17, 2014 and May 17, 2015, subject to Mr. Barton's continued service with the Issuer on the applicable vesting date.
- (3) The option vests in three equal annual installments, with one-third (1/3rd) vesting on March 6, 2015, 2016 and 2017, subject to Mr. Barton's continued service with the Issuer on the applicable vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Reporting Owners 2

#### Edgar Filing: Alliqua BioMedical, Inc. - Form 3

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.	